| Literature DB >> 29374275 |
Youmna Ghaleb1,2,3, Sandy Elbitar1,2,3, Petra El Khoury1,3, Eric Bruckert4, Valérie Carreau4, Alain Carrié5, Philippe Moulin6, Mathilde Di-Filippo7, Sybil Charriere6, Harout Iliozer6, Michel Farnier8, Gérald Luc9, Jean-Pierre Rabès10,11, Catherine Boileau1,2,12, Marianne Abifadel1,3, Mathilde Varret13,14.
Abstract
Familial hypercholesterolemia (FH) is caused by mutations in LDLR (low-density lipoprotein receptor), APOB (apolipoprotein B), PCSK9 (proprotein convertase subtilisin/kexin type 9), or APOE (apolipoprotein E) genes in approximately 80% of the cases. Polygenic forms of hypercholesterolemia may be present among patients clinically diagnosed with FH but with no identified mutation (FH mutation-negative (FH/M-)). To address whether polygenic forms may explain phenocopies in FH families, we calculated a 6-single-nucleotide polymorphism (SNP) genetic risk score (GRS) in all members from five French FH families where a mutation was identified (FH/M+) as well as some phenocopies (FH/M-). In two families, three FH/M- patients present a high GRS suggesting a polygenic hypercholesterolemia for these phenocopies. However, a high GRS is also observed in nine FH/M+ patients and in four unaffected relatives from three families. These observations indicate that the GRS does not seem to be a good diagnostic tool at the individual level. Nevertheless, the GRS seems to be a contributor of the severity of hypercholesterolemia since patients who cumulate a mutation and a high GRS exhibit higher low-density lipoprotein cholesterol levels when compared to patients with only FH (p = 0.054) or only polygenic hypercholesterolemia (p = 0.0039). In conclusion, the GRS can be used as a marker of the severity of hypercholesterolemia but does not seem to be a reliable tool to distinguish phenocopies within FH families.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29374275 PMCID: PMC5891487 DOI: 10.1038/s41431-017-0078-y
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246